Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium
Open Access
- 31 March 2012
- journal article
- Published by Springer Nature in Malaria Journal
- Vol. 11 (1), 102
- https://doi.org/10.1186/1475-2875-11-102
Abstract
Intravenous (IV) artesunate is the treatment of choice for severe malaria. In Europe, however, no GMP-manufactured product is available and treatment data in European travellers are scarce. Fortunately, artesunate became available in the Netherlands and Belgium through a named patient programme. This is the largest case series of artesunate treated patients with severe malaria in Europe.Keywords
This publication has 24 references indexed in Scilit:
- Continuous‐Flow Synthesis of the Anti‐Malaria Drug ArtemisininAngewandte Chemie International Edition, 2012
- Artesunate Induces Oxidative DNA Damage, Sustained DNA Double-Strand Breaks, and the ATM/ATR Damage Response in Cancer CellsMolecular Cancer Therapeutics, 2011
- Treatment of imported severe malaria with artesunate instead of quinine - more evidence needed?Malaria Journal, 2011
- Intravenous Artesunate for Severe Malaria in Travelers, EuropeEmerging Infectious Diseases, 2011
- Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trialThe Lancet, 2010
- Severe Imported Falciparum Malaria: A Cohort Study in 400 Critically Ill AdultsPLOS ONE, 2010
- Efficacy and safety of exchange transfusion as an adjunct therapy for severe Plasmodium falciparum malaria in nonimmune travelers: a 10‐year single‐center experience with a standardized treatment protocolTransfusion, 2010
- Severe Malaria and Artesunate Treatment, NorwayEmerging Infectious Diseases, 2008
- Qinghaosu (Artemisinin): The Price of SuccessScience, 2008
- Resurgence of Blackwater Fever in Long-Term European Expatriates in Africa: Report of 21 Cases and ReviewClinical Infectious Diseases, 2001